Ticker

Analyst Price Targets — HSCS

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
December 19, 2022 8:32 amMaxim Group$3.00$0.90Benzinga Maxim Group Maintains Buy on Heart Test Laboratories, Lowers Price Target to $3

Latest News for HSCS

University of West England Adopts HeartSciences' MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center

Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.    (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that the University of the West of England (“UWE”) has adopted the Company's MyoVista Insights™ platform and…

GlobeNewsWire • Feb 5, 2026
Cibolo Health Designates HeartSciences' MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals

Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc.   (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG…

GlobeNewsWire • Jan 29, 2026
HeartSciences (NASDAQ:HSCS) & Health Catalyst (NASDAQ:HCAT) Critical Analysis

HeartSciences (NASDAQ: HSCS - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations. Profitability This table compares HeartSciences and Health Catalyst's

Defense World • Dec 21, 2025
HeartSciences Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update

Southlake, TX, Dec. 15, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq: HSCS) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today reported financial results for its fiscal second quarter ended October 31, 2025 (“FQ2 2026”) and provided a business update.

GlobeNewsWire • Dec 15, 2025

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for HSCS.

No House trades found for HSCS.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top